Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Bone Marrow Transplantation|October 18, 2000
Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantationC Martínez, E Carreras, M Rovira, et al.
Current Medicinal Chemistry|March 10, 2018
Chronic Kidney Disease and the Search for New Biomarkers for Early DiagnosisAlma L Saucedo, Marlene M Perales-Quintana, David Paniagua-Vega, et al.
Leukemia Research|April 13, 2001
Allogenic stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institutionC Martínez, E Carreras, M Rovira, et al.
Medicina Clinica|December 22, 1998
[Laparoscopic splenectomy as an alternative to open surgery in the treatment of autoimmune thrombocytopenia]J J Espert, E M Targarona, F Cervantes, et al.
British Journal of Haematology|June 14, 2001
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomasJ Bladé, M Perales, L Rosiñol, et al.
Oxidative Medicine and Cellular Longevity|April 13, 2018
Nephroprotective Effect of Sonchus oleraceus Extract against Kidney Injury Induced by Ischemia-Reperfusion in Wistar RatsLiliana Torres-González, Eduardo Cienfuegos-Pecina, Marlene M Perales-Quintana, et al.
Medicina Clinica|September 3, 1999
[The autologous transplantation of hematopoietic precursors on an outpatient basis: an analysis of its feasibility at the Hospital Clínic de Barcelona]S Rives, E Carreras, M Rovira, et al.
Cancer|April 13, 2001
Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimensL Villela, A López-Guillermo, S Montoto, et al.
European Journal of Haematology|August 4, 1998
Risk of relapse and clinico-pathological features in 103 patients with diffuse large-cell lymphoma in complete response after first-line treatmentL Sanz, A López-Guillermo, C Martínez, et al.
Revista Espanola De Quimioterapia : Publicacion Oficial De La Sociedad Espanola De Quimioterapia|October 24, 2019
Dalbavancin for treating prosthetic joint infections caused by Gram-positive bacteria: A proposal for a low dose strategy. A retrospective cohort studyL Buzón Martín, M Mora Fernández, J M Perales Ruiz, et al.
Pageof 3